NVAX: Strategic shift to licensing and Matrix-M partnerships drives growth in vaccines and oncology
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones, and a leaner structure position the company for sustainable growth and global…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.